EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

Revance’s Botox rival turned away by FDA after inspectors flagged manufacturing ‘deficiencies’

Despite a pandemic delay and an FDA warning about quality control and record-keeping problems at a production site, Revance insisted it was optimistic the agency woul...
Continue Reading →
Regional News

As Revance nears a potential launch for its Botox rival, AbbVie sues for patent infringement

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it...
Continue Reading →
Catalyst: 12th January 2026
Quotient